CellaVision prolongs cooperation with Kitron
CellaVision, which develops and sells digital morphology products for the routine analysis of blood and other body fluids, signs a new agreement with the contract manufacturer Kitron AB in Karlskoga. The agreement spans for two years and involves manufacturing of CellaVision's analysis instruments of a worth of around SEK 25 million annually.
The new agreement will replace the previous agreement from 2005 and is signed in relation to the restructuring of Kitron and the company's manufacturing move from Flen to Karlskoga. The cooperation involves manufacturing of the analysis instrument CellaVision® DM96 and further development of the product's optics and optronics.
"Extensive experience, specialization, and a continuous strive to improve are qualities that make Kitron a partner who complements our core competences. Kitron understands the special demands that characterize our industry and affect the manufacturing of our products," says Yvonne Mårtensson, CEO of CellaVision.
"We are proud of CellaVision's continued confidence in us and our manufacturing of their products for clients worldwide. We are impressed by CellaVision's success in the market and are glad to be able to contribute with our competence in both manufacturing and development," says Johannes Lind, General Manager Kitron Sweden.
For more information, please contact:
Yvonne Mårtensson, CEO, CellaVision AB
Phone: +4646-286 44 00. E-mail:
Johannes Lind, General Manager Kitron Sweden
Phone: +46736-68 33 20. E-mail:
About Kitron
Kitron is one of Scandinavia's leading companies in development, industrialization and production of electronics for the data/telecom, defense/marine, medical, automotive and other industries. The manufacturing site in Karlskoga is dedicated to Medical Device Production. See also
About CellaVision
CellaVision AB develops, markets, and sells the market leading image analysis based systems for routine analysis of blood and other body fluids. The company has a core competence in development of software for automatic image analysis of cells and cell changes for applications in health and medical care. The company develops and markets systems for automatic differentials of white blood cells and red morphology, and software for education and quality assurance of differentials. The company's associates have expertise in advanced imaging analysis, artificial intelligence, and automated microscopy.
The company headquarters are in Lund, Sweden and has subsidiaries in Jupiter, FL, USA, and Toronto, ON, Canada. For more information, visit
CellaVision's share is listed on First North at the OMX Stockholm Stock Exchange. The company's Certified Advisor is Remium AB.